Search
-
Improving access to healthcare by removing transportation barriers
Read how understanding the gaps and issues people face can give transportation planners, policymakers, and healthcare providers the data they need to tackle these problems in their communities.
-
Americans want to live healthier in 2025. Here’s what that looks like, from alcohol to exercise
Americans’ resolutions for 2025 revolve around health. But what that means to them varies by age.
-
Where Americans stand on healthcare heading into Trump’s second term
Below are five charts on how Americans feel about the state of U.S. healthcare, Trump’s health-related cabinet picks, and some of the key policies his nominees want to implement
-
37 questions for 2025 and beyond
As the biggest election year in human history draws to a close, the Ipsos Consumer Tracker looks at the issues that will shape the U.S. under Trump's second term.
-
Here's what we resolve for 2025
Three in four Americans are resolving to eat healthier and exercise more in 2025, according to the Ipsos Consumer Tracker.
-
Customer Perspective: An Ipsos Podcast
An Ipsos podcast series exploring best practices in customer experience strategies, mystery shopping and channel performance.
-
[SERIES RECORDING] KEYS – The Year in Review
Join Ipsos for its complimentary KEYS webinar series dedicated to helping brands and organizations better understand the dynamics of today as they prepare for tomorrow.
-
Ipsos Predictions Survey 2025: Positivity about how this year has gone highest since before the pandemic
The Ipsos Predictions Survey 2025 is a 33-country study which looks at people’s expectations and predictions for the year ahead.
-
[RECORDING] HIMSS: Innovations for more equitable obesity care
Ipsos’ Jackie Ilacqua joins a HIMSS panel discussion on the foresight to equitable obesity care and what's required within health system management to adapt successfully.
-
U.S. Biosimilars: Greater Access and New Commercial Models
Read more about the primary considerations that manufacturers – of both biosimilars and originator products – must factor into strategic plans going forward.